Dapagliflozin in Type 1 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

July 29, 2016

Study Completion Date

February 8, 2017

Conditions
Fasting GlucoseGlucose ExcursionGlycemic Control
Interventions
DRUG

Dapagliflozin

euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin

Trial Locations (1)

6020

Medical University Innsbruck, Department of Internal Medicine I, Innsbruck

All Listed Sponsors
collaborator

Medical University of Graz

OTHER

collaborator

University of Bern

OTHER

lead

Medical University Innsbruck

OTHER

NCT02211742 - Dapagliflozin in Type 1 Diabetes | Biotech Hunter | Biotech Hunter